Payload Information
General Information of This Payload
| Payload ID | PAY0MMXXU |
|||||
|---|---|---|---|---|---|---|
| Name | Ceritinib |
|||||
| Synonyms |
Ceritinib
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C28H36ClN5O3S |
|||||
| Isosmiles | CC(S(C1=CC=CC=C1NC2=C(Cl)C=NC(NC3=C(OC(C)C)C=C(C(C)=C3)C4CCNCC4)=N2)(=O)=O)C |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
|
|||||
| InChIKey |
VERWOWGGCGHDQE-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
558.148 |
Polar area |
105.24 |
||
Complexity |
1340.780847 |
xlogp Value |
6.36192 |
|||
Heavy Count |
38 |
Rot Bonds |
9 |
|||
Hbond acc |
8 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.35 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.35 | % |
Vero C1008 cells
|
Normal
|
||
| Cellular activity | -1 | % |
Sf21 cells
|
Normal
|
||
| Cell-based Growth Rate | -100 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -100 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -100 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -26 | % |
HEK-293T cells
|
Normal
|
||
| Cellular activity | -3 | % |
Sf21 cells
|
Normal
|
||
| Cell-based Growth Rate | -31 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -33 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -35 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -35 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -38 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -4.06 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | -40 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -42 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -45 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -48 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -49 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -5.81 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | -52 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -52 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -57 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -57 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -58 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -60 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -60 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -61 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -62 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -63 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -64 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -66 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -66 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -68 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -74 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -78 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -79 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -82 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -82 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -84 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -86 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -87 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -87 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -88 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -91 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -91 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -92 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -92 | % |
HEK-293T cells
|
Normal
|
||
| Cell-based Growth Rate | -93 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -94 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -95 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -96 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -97 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -98 | % |
U2OS cells
|
Osteosarcoma
|
||
| Cell-based Growth Rate | -99 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Growth Rate | -99 | % |
Fibroblast cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 0 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0 | % |
Vero C1008 cells
|
Normal
|
||
| Cellular activity | 0.55 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 0.91 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 1 | log10RLU | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1.17 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 1.55 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 1.88 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 1.93 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 1.99 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 10.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 101 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 101 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 102 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 102 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 102 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 103 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 103 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 104 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 104 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 104 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 105 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 105 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 105 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 106 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 106 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 106 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 107 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 107 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 107 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 108 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 109 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 11 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 11.77 | % |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
||
| Cellular activity | 112 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 113 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 118 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 12.32 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 12.62 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 123 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 123 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 13 | % |
Sf21 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 13.5 | % |
Sf9 cells
|
Normal
|
||
| Tumor Growth Inhibition (TGI) | 14 | % |
BaF3 cells
|
Normal
|
||
| Cellular activity | 14.15 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 14.93 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 15.21 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 18.02 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 2 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 2.07 | % |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
||
| Cellular activity | 20.4 | % |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
||
| Cellular activity | 24 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 24.08 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 26 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 27.27 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 28.18 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 3 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 3.61 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 3.86 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 33.92 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 34 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 36 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 38 | % |
Sf9 cells
|
Normal
|
||
| Cellular activity | 4.19 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 4.19 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 4.45 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 4.83 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Growth Rate | 45 | % |
U2OS cells
|
Osteosarcoma
|
||
| Tumor Growth Inhibition (TGI) | 49 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 5.87 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 52.82 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 55 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 55.92 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 57.79 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 59.98 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 6 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 6 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 6.24 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 6.94 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 60.69 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 63 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 64 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 65 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 69 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 7 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 7.07 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 70 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 70 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 70 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 73 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 74 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 76 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 8.527 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 80 | % |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Cellular activity | 80 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 81 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 81 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 81 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 81.4 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 81.88 | % |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
||
| Cellular activity | 82 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 82 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 83 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 83 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 83 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 83 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 84 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 84 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 85 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 85 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 85 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 87 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 87 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 87.32 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 87.37 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 87.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 88 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 88.06 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 88.21 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 89 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 89 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 9 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 9 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 9.02 | % |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 90 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 90 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 90.21 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 91 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 91 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 91.29 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 92 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 92 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 93 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 94 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 94 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 96 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 96 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 96 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 96 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 96 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 97 | % |
BaF3 cells
|
Normal
|
||
| Cellular activity | 97 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 98 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 98 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 98 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 98 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 99 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 99 | % |
Sf21 cells
|
Normal
|
||
| Cellular activity | 99 | % |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.25 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.61 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.63 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.83 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.1 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.9 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10.7 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
NCI-H1975 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
HEK-293T cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1007 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 101 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1010 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1010 | nM |
EA.hy 926 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 102.6 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1020 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1020 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1030 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1030 | nM |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10320 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 104 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| 90% Inhibitory Concentration (IC90) | 1042 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1043 | nM |
A-375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1043 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1045 | nM |
SK-N-AS cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 107 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1070 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1070 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 108 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 109 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 109.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 111.3 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| 90% Inhibitory Concentration (IC90) | 112 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 112 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1120 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 114.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1140 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1164 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 117 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 119 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1200 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 121 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 122 | nM |
SU-DHL-1 cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Effective Concentration (EC50) | 122 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| 90% Inhibitory Concentration (IC90) | 1227 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1250 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1250 | nM | Undisclosed | Undisclosed | Undisclosed | |
| 90% Inhibitory Concentration (IC90) | 1270 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1270 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1280 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1300 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| 90% Inhibitory Concentration (IC90) | 1316 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1320 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1339 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 141.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 142 | nM |
Kelly cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1430 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
SU-DHL-1 cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Effective Concentration (EC50) | 15 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 150 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 158.49 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 159 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1610 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1610 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 162 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1620 | nM |
NCI-H1299 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 164 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1650 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| 90% Inhibitory Concentration (IC90) | 166 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1666 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 169.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1694 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17.23 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 172 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1740 | nM |
NCI-H1299 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1754 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 18 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1820 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1820 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1829 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1830 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 186 | nM |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1870 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 190 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1930 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1947 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 195 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 197 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 198 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1980 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 199.53 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1995.26 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
SR cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >2000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >2000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >2000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| 90% Inhibitory Concentration (IC90) | 201 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 201 | nM | Undisclosed | Undisclosed | Undisclosed | |
| 90% Inhibitory Concentration (IC90) | 202 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2142 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2156 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2160 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2160 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2160 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2180 | nM |
NCI-H1581 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.1 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.8 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.8 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2240 | nM |
AGS cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2240 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 226 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| 90% Inhibitory Concentration (IC90) | 229 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 230 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2304 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2306 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2310 | nM |
NCI-H1581 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 234 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 24.7 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2477 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2477 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 25 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 25 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 2500 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 2500 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2512 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 26 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2660 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 2660 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 27.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2700 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2708 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
||
| 90% Inhibitory Concentration (IC90) | 271 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 271 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2710 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2720 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2727 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2747 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2770 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 28.4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 28.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 283 | nM |
BaF3 cells
|
Normal
|
||
| 90% Inhibitory Concentration (IC90) | 2841 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2855 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2860 | nM |
Vero cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2900 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2900 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2918 | nM |
Jurkat cells
|
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2920 | nM |
NCI-H1299 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.2 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.2 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
Sf9 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.94 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | >3000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 3000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 303 | nM |
SK-N-SH cells
|
Neuroblastoma
|
||
| 90% Inhibitory Concentration (IC90) | 304 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 304 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3050 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3143 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3170 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 319 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 319.5 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 320 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 3210 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3250 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 33 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3360 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 341 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 349 | nM |
SK-N-FI cells
|
Neuroblastoma
|
||
| Half Maximal Effective Concentration (EC50) | 3490 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 35000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3510 | nM |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 354 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 363 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 370 | nM |
SH-SY5Y cells
|
Bone marrow neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3730 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 38 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 38 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 38 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 38 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 39 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 39 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3970 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 40.7 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 406 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4080 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 41 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 41 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 41 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 410 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| 90% Inhibitory Concentration (IC90) | 42 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42 | nM |
BaF3 cells
|
Normal
|
||
| 90% Inhibitory Concentration (IC90) | 420 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4210 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 43 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 43 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 430 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 437 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 44 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 444 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 4440 | nM | Undisclosed | Undisclosed | Undisclosed | |
| 90% Inhibitory Concentration (IC90) | 449 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 451 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 46000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 47 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 47.65 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4720 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 488 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 490 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | >5000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 501.19 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 506 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 510 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 524.3 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 54.9 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 549 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5512 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 560 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 565 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 57 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 576.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 576.6 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 580 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 590 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 593 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM | Undisclosed | Undisclosed | Undisclosed | |
| 90% Inhibitory Concentration (IC90) | 61 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 610 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 63.42 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 64 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 64 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 660 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 668 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 67 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 67 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 672 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 6840 | nM |
Vero cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 685.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 697 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7.11 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7.6 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 71 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 72 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 726 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 728 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| 90% Inhibitory Concentration (IC90) | 734 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 75 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 75 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 75 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Cytotoxic Concentration (CC50) | 75 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 75 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 75 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 76 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 760 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 770 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 780.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 780.5 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 780.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 79 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 79 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7920 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 80 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 81 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 810 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8350 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 84 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 840 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 845 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 850 | nM |
U2OS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 86.4 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 89 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 895 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9.6 | nM |
Sf21 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 91 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 91000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 92 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 93 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 940 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 941 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 950 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 96 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 97 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 97 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 98.5 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| 90% Inhibitory Concentration (IC90) | 99 | nM |
BaF3 cells
|
Normal
|
||
| 90% Inhibitory Concentration (IC90) | 99 | nM |
BaF3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 99 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
Each Antibody-drug Conjugate Related to This Payload